This article reviews previous studies assessing *Fusarium* and *Penicillium* mycotoxin exposure, toxicity, and risk mitigation using a range of intestinal epithelial cell (IEC) and immune cell models cultured in different systems that can be used as efficient in vitro models of in vivo intestinal barrier microenvironment, considering their suitability and limitations.

1. Introduction {#sec1-toxins-12-00146}
===============

Mycotoxins are toxic secondary metabolites produced by filamentous fungi that predominantly belong to species from the *Aspergillus, Fusarium,* and *Penicillium* genera. Over 500 different classes of mycotoxins have been discovered, many of which have unknown mechanisms of action (MOA) \[[@B1-toxins-12-00146]\]. Ingestion of mycotoxins can lead to mycotoxicosis in both animals and humans, and at subclinical concentrations may affect animal production and adulterate food animal by-products. These toxic compounds of global concern are commonly detected as contaminants in a variety of commodities of plant origin, especially cereal grains, and are therefore often detected in animal feeds. Mycotoxins can also be found in animal-derived products such as meat, eggs, milk, and milk derivatives due to their carry-over from animals that have consumed contaminated feeds \[[@B2-toxins-12-00146],[@B3-toxins-12-00146],[@B4-toxins-12-00146]\]. Natural co-occurrence of mycotoxins with potential additive, antagonistic, or synergistic effects more commonly occurs in foods and feeds than single mycotoxin contaminants \[[@B5-toxins-12-00146]\]. Mycotoxins inflict high annual economic losses worldwide due to condemned agricultural commodities as well as reduced animal and human health \[[@B6-toxins-12-00146]\]. Weather conditions associated with climate change have been predicted to favor more fungal contamination of foods and feeds as temperature and moisture are major factors influencing fungal growth and mycotoxin production \[[@B2-toxins-12-00146],[@B7-toxins-12-00146]\]. Global trade of food and feed commodities contributes to the worldwide dispersal of mycotoxins \[[@B5-toxins-12-00146]\].

A wealth of toxicity and mechanistic studies have been conducted on mycotoxins at the cellular level using kidney cells and blood lymphocytes \[[@B5-toxins-12-00146],[@B8-toxins-12-00146]\], as well as animal performance studies \[[@B9-toxins-12-00146]\]. However, the effects of mycotoxins on the intestine should be more thoroughly considered and assessed for the following reasons. Firstly, the intestinal epithelium is the initial site of exposure following the ingestion of mycotoxins and the first physical barrier that limits their entry into the animal \[[@B10-toxins-12-00146]\]; damage to this barrier could also facilitate entry of luminal microbes, antigens, and other food contaminants. Secondly, the intestinal mucosa possesses the largest single compartment of the immune system underlying the epithelial lining \[[@B11-toxins-12-00146]\]. Collectively, the gut-associated lymphoid system and intestinal epithelial cells (IECs) forming the intestinal barrier cross-talk with each other to maintain homeostasis of both the intestine and the immune system to elicit an appropriate immune response during microbial infection and to repair damaged tissues \[[@B10-toxins-12-00146],[@B12-toxins-12-00146],[@B13-toxins-12-00146],[@B14-toxins-12-00146],[@B15-toxins-12-00146]\]. Mycotoxin exposure could render this important immunological barrier dysfunctional and this, combined with disrupted physical barrier function, could increase host susceptibility to disease. Thirdly, IECs are equipped with metabolizing enzymes and protein pumps that regulate absorption and biotransformation of xenobiotics as well as the possible efflux of metabolites back to the intestinal lumen. Mycotoxins may be able to alter the expression and activity of IEC proteins involved in absorption, efflux, and biotransformation \[[@B16-toxins-12-00146]\], which could compromise their ability to regulate the bioavailability of other xenobiotics and nutrients. A fourth reason is that IECs may be repeatedly exposed to high concentrations of mycotoxins, which could increase the likelihood of impairment to the intestinal barrier function \[[@B17-toxins-12-00146],[@B18-toxins-12-00146]\]. Specifically, after absorption by IECs, mycotoxins such as Ochratoxin A (OTA) and zearalenone (ZEA) could be returned to intestinal lumen either by IECs through efflux proteins, or via bile after undergoing entero-hepatic circulation \[[@B10-toxins-12-00146],[@B16-toxins-12-00146],[@B19-toxins-12-00146],[@B20-toxins-12-00146]\]. This recirculation could result in the reabsorption of mycotoxins and prolonged exposure of IECs at the intestinal barrier, which could increase the risk of mycotoxins interacting with each other and other xenobiotics \[[@B5-toxins-12-00146],[@B21-toxins-12-00146]\]. A fifth reason is that IECs undergo continuous renewal in order to maintain barrier function, and a number of mycotoxins are known to inhibit protein synthesis \[[@B22-toxins-12-00146],[@B23-toxins-12-00146]\], which could impair the renewal process. A sixth reason is a potential interaction between mycotoxins and gut microbiota. Rumen and intestinal microflora are able to metabolically inactivate certain mycotoxins \[[@B9-toxins-12-00146],[@B24-toxins-12-00146]\], however, some mycotoxins that exhibit antimicrobial activity may reduce detoxification efficiency \[[@B25-toxins-12-00146],[@B26-toxins-12-00146],[@B27-toxins-12-00146]\]. Since the intestinal microbiota also contributes to intestinal barrier function, immune system development, and mediates the production of neurotransmitters associated with brain function \[[@B28-toxins-12-00146],[@B29-toxins-12-00146],[@B30-toxins-12-00146]\], disrupted intestinal microbial populations could also potentially impair gut--immune and gut--brain communication.

The effects of various mycotoxins on the intestinal mucosal components have been studied both in-vivo and in-vitro. Since in-vitro cell culture models provide a cost-effective and high throughput means for the initial screening and assessment of mycotoxins, and mitigation approaches, this review will provide a summary of in vitro studies that have been carried out on individual and combined mycotoxins acting on the intestinal epithelial and gut immunological barrier using IEC and immune cell models, and explore different in-vitro IEC or co-culture models and their suitability and limitations for assessing mycotoxin exposure. The mycotoxins most commonly addressed in this review include deoxynivalenol (DON), ZEA, aflatoxin B1 (AFB1), citrinin (CIT), OTA, and mycophenolic acid (MPA) in terms of their prevalence, toxicity, and occurrence of pre- and post-harvest in animal feeds. The review also summarizes the in-vitro assessment of mycotoxin detoxifying agents (i.e. mycotoxin binders and modifiers) as feed additives that are widely used in the animal feed industry to mitigate the risk of exposure. Lastly, this review points out the need for co-culture models that are better able to more physiologically and immunologically reflect the intestinal mucosa to better assess the effects of mycotoxins on the intestine.

2. Mycotoxins {#sec2-toxins-12-00146}
=============

Mycotoxins are structurally diverse low-molecular-weight metabolites that are chemically and thermally stable \[[@B10-toxins-12-00146],[@B31-toxins-12-00146]\]. The three most predominant mycotoxin-producing fungi species *Aspergillus*, *Fusarium,* and *Penicillium* can be classified as either field (*Fusarium* spp. ) or storage fungi (*Aspergillus* spp. and *Penicillium* spp.) \[[@B32-toxins-12-00146]\]; field fungi produce mycotoxins (DON and ZEA) prior to harvest \[[@B33-toxins-12-00146],[@B34-toxins-12-00146]\], while storage fungi initially colonize plants prior to harvest and continue to grow and produce mycotoxins (AFB1, CIT, OTA, and MPA) under improper grain and silage storage conditions that favor fungal development and mycotoxin production \[[@B33-toxins-12-00146],[@B35-toxins-12-00146],[@B36-toxins-12-00146],[@B37-toxins-12-00146]\].

DON is one of the most commonly detected mycotoxins in cereal crops such as wheat, corn, barley, and rye \[[@B38-toxins-12-00146]\]. Various organ systems can be the targets of DON. Ingestion, for example, causes nausea and vomiting through interactions with the neural dopaminergic system; because of this, DON is also referred to as vomitoxin \[[@B39-toxins-12-00146],[@B40-toxins-12-00146],[@B41-toxins-12-00146]\]. The immune system is another target for DON; at high concentrations, DON is an immunosuppressant, whereas, at lower concentrations, DON may stimulate the immune system \[[@B39-toxins-12-00146],[@B42-toxins-12-00146]\]. DON also induces caspase-mediated apoptosis via activation of MAPK signaling pathways \[[@B39-toxins-12-00146]\]. One MOA of DON includes disruption of protein translation via binding to the 60S ribosomal subunit of peptidyl transferase \[[@B43-toxins-12-00146]\].

ZEA is another major mycotoxin produced by various *Fusarium* species. ZEA is classified as an estrogenic mycotoxin because it resembles human 17β-estradiol and binds to and activates estrogen receptors expressed mainly within the reproductive system. ZEA has been shown to also be immunotoxic, hepatotoxic, hematotoxic, and genotoxic, which may be partially attributed to ZEA contributing to oxidative DNA damage and cellular apoptosis induced by the production of reactive oxygen species \[[@B44-toxins-12-00146],[@B45-toxins-12-00146],[@B46-toxins-12-00146],[@B47-toxins-12-00146],[@B48-toxins-12-00146],[@B49-toxins-12-00146]\].

Aflatoxins are produced mainly by species of *Aspergillus flavus* and *Aspergillus parasiticus* \[[@B50-toxins-12-00146]\]. AFB1 is the most potent member of the aflatoxin family based on its well-characterized carcinogenicity leading to hepatocellular carcinoma in both humans and animals \[[@B51-toxins-12-00146]\]. It also causes malnutrition, suppresses growth, and modulates immune function \[[@B52-toxins-12-00146]\]. The formation of DNA adducts and the ability to cause oxidative damage might contribute to AFB1 cytotoxicity and carcinogenicity \[[@B53-toxins-12-00146]\].

CIT is produced predominantly by *Penicillium* spp. \[[@B38-toxins-12-00146]\]. Several species of *Aspergillus* and *Monascus* are also producers of CIT \[[@B36-toxins-12-00146],[@B38-toxins-12-00146]\]. CIT naturally contaminates a variety of foods and feeds such as nuts, grains, barley, wheat, and corn, mainly during storage \[[@B6-toxins-12-00146]\], and has been shown to be nephrotoxic in all tested animal species \[[@B38-toxins-12-00146]\]. CIT genotoxicity is controversial, showing both positive and negative results using various in-vitro systems \[[@B54-toxins-12-00146],[@B55-toxins-12-00146],[@B56-toxins-12-00146]\].

OTA is produced by *Penicillium* spp. and various *Aspergillus* spp., and it is the most prominent among the family of ochratoxins \[[@B57-toxins-12-00146]\]. OTA has been found to contaminate cereals and cereal by-products such as wheat, rye and barley \[[@B10-toxins-12-00146],[@B38-toxins-12-00146]\], and has been detected in animal products including pork and milk \[[@B58-toxins-12-00146]\]. OTA is a nephrotoxin to all animal species including humans \[[@B3-toxins-12-00146],[@B59-toxins-12-00146],[@B60-toxins-12-00146],[@B61-toxins-12-00146]\]. OTA has also been shown to be a teratogen, hepatotoxin, immunosuppressant, and carcinogen in various animal species including humans \[[@B62-toxins-12-00146],[@B63-toxins-12-00146]\]. The number of MOAs by which OTA interferes with cellular functions has been determined. OTA inhibits protein synthesis through inhibiting phenylalanyl-tRNA synthetase, thus phenylalanine metabolism. Mitochondria are also targeted by OTA through inhibiting ATP production and inducing the production of reactive oxygen and nitrogen species. OTA also disrupts cell-cycle progression by targeting the cyclin--CDK system, disrupting mitosis, and causing chromosomal instability \[[@B64-toxins-12-00146],[@B65-toxins-12-00146],[@B66-toxins-12-00146],[@B67-toxins-12-00146],[@B68-toxins-12-00146],[@B69-toxins-12-00146],[@B70-toxins-12-00146]\]. Lastly, OTA can also induce DNA adducts, particularly deoxyguanosine (dG) adducts \[[@B67-toxins-12-00146],[@B71-toxins-12-00146],[@B72-toxins-12-00146]\].

The mycotoxin MPA is produced by *Penicillium roqueforti* fungi, which is a main silage spoiler and the most prevalent post-harvest fungi found in forage silages due to its capacity to grow in low-oxygen and high carbon dioxide as well as acidic and cold environmental conditions \[[@B37-toxins-12-00146],[@B73-toxins-12-00146],[@B74-toxins-12-00146],[@B75-toxins-12-00146],[@B76-toxins-12-00146],[@B77-toxins-12-00146],[@B78-toxins-12-00146]\]. MPA is one of the "emerging" mycotoxins that are being detected in feedstuffs. It is frequently detected in forages, particularly silage \[[@B79-toxins-12-00146]\]. MPA is able to inhibit B and T lymphocyte proliferation and inhibit the production of cytotoxic T cells \[[@B80-toxins-12-00146],[@B81-toxins-12-00146]\]. MPA also exhibits antibacterial, antifungal, antitumor, and antiviral properties \[[@B80-toxins-12-00146],[@B82-toxins-12-00146]\]. However, MPA's immunosuppressive properties may increase the susceptibility of exposed animals to infectious diseases and sensitivity to other mycotoxins \[[@B83-toxins-12-00146]\], and MPA's antimicrobial properties could disrupt the normal function of the microflora in ruminants, including the detoxication of other *Penicillium* mycotoxins \[[@B84-toxins-12-00146],[@B85-toxins-12-00146]\]

3. The Intestinal Barrier {#sec3-toxins-12-00146}
=========================

3.1. Physical Barrier {#sec3dot1-toxins-12-00146}
---------------------

The intestine forms a physical barrier between the microbial-rich luminal environment and sterile internal host tissues \[[@B86-toxins-12-00146]\]. This selectively permeable barrier allows for the exchange of nutrients and antigens, while preventing the penetration of opportunistic commensal and pathogenic microorganisms and their toxins into host tissues \[[@B87-toxins-12-00146],[@B88-toxins-12-00146]\]. The intestinal barrier consists of an external "physical" barrier mainly formed by mucous-coated IECs, and an underlying functional "immunological" barrier \[[@B13-toxins-12-00146],[@B89-toxins-12-00146]\]. Collectively, these barriers communicate and interact with each other to maintain intestinal barrier function and optimize the outcome of the host defense against microbial infection \[[@B13-toxins-12-00146],[@B89-toxins-12-00146]\].

The intestinal physical barrier is made up of a variety of polarized IECs. Five major specialized mucosal IEC lineages have been found to differentiate from multipotential stem cells located at the base of the intestinal crypts of Lieberkühn; these include enterocytes, which are the most abundant IECs \[[@B13-toxins-12-00146],[@B90-toxins-12-00146]\], goblet cells, enteroendocrine cells, Paneth cells, and microfold (M) cells. These specialized IECs reside in different proportions at different locations along the epithelium and carry out different functions. Goblet cells contribute to intestinal physical barrier function by secreting mucus containing mucin proteins; these mucins help prevent attachment of commensal and pathogenic bacteria to the intestinal epithelium \[[@B91-toxins-12-00146]\]. Intercellular junctions, including tight junctions (TJs) and adhesion molecules, connect adjacent IECs to maintain physical barrier function. The TJs are the major functional elements that seal the paracellular spaces; thus, they play a key role in regulating the flow of ions and small molecules and in preventing fluid leaking between the lumen and underlying tissues \[[@B92-toxins-12-00146],[@B93-toxins-12-00146]\]. TJs are composed of transmembrane proteins and cytoplasmic scaffold proteins. The transmembrane proteins, whose extracellular domains horizontally cross the plasma membrane of adjacent cells, including occludin (OCLN), the claudin protein family (CLDNs), and the junctional adhesion molecules marvel D3, and tricellulin \[[@B92-toxins-12-00146]\]. The cytoplasmic scaffold proteins are intracellular TJs that link the actin cytoskeleton to transmembrane TJs, and the zonula occludin proteins (ZOs) are an important group \[[@B92-toxins-12-00146]\].

Commensal microbiota residing within the intestine can also contribute to the intestinal barrier function by competitively excluding attachment sites and nutrients from pathogenic microorganisms \[[@B13-toxins-12-00146]\]. The commensal barrier is beyond the scope of this review; however, it is worth noting that commensal microorganisms can become opportunistic pathogens when the intestinal barrier function is compromised \[[@B94-toxins-12-00146],[@B95-toxins-12-00146]\].

3.2. Immunological Barrier {#sec3dot2-toxins-12-00146}
--------------------------

### 3.2.1. IECs and Intraepithelial Lymphocytes (IELs) {#sec3dot2dot1-toxins-12-00146}

The intestine also possesses a functional innate and acquired immunological barrier that provides localized defense when potentially harmful luminal microorganisms, or their toxins, penetrate the host epithelial barrier. In addition to their physical barrier function discussed above, differentially specialized IECs are an important component of the host innate immune system and are considered the first line of defense provided by the immunological barrier \[[@B96-toxins-12-00146]\]. Paneth cells, for example, are specialized secretory cells that produce large amounts of antimicrobial peptides and proteins such as β-defensins and cathelicidin, and antimicrobial enzymes such as lysozyme \[[@B96-toxins-12-00146],[@B97-toxins-12-00146]\]. Enterocytes, in addition to their specialized role in digestion and nutrient absorption, can also serve as luminal sensors for the immune system since they possess large numbers of pattern-recognition receptors (PRRs) that are expressed both on the cell surface and within the cell. These PRRs recognize conserved structure molecules displayed on the surface of bacteria, fungi, parasites, and viruses that are referred to as pathogen-associated molecular patterns \[[@B13-toxins-12-00146],[@B15-toxins-12-00146],[@B98-toxins-12-00146]\]. Membrane PRRs include the Toll-like receptors (TLRs), and cytoplasmic PRRs include the NOD-like receptors such as NOD1 and NOD2 \[[@B99-toxins-12-00146],[@B100-toxins-12-00146]\]. In addition to producing mucus, goblet cells also have the capacity to take up luminal material and present antigens to dendritic cells in the lamina propria \[[@B91-toxins-12-00146],[@B101-toxins-12-00146],[@B102-toxins-12-00146]\].

Interspersed amongst the IECs lining the epithelium are highly abundant long-living intraepithelial lymphocytes (IELs); the estimated IEL to IEC ratio in the human small intestine is 1:10 \[[@B103-toxins-12-00146]\]. These motile cells have diverse lineages, but the majority can be broadly classified as either "unconventional" IELs that contribute to the innate immunological barrier, or "conventional" IELs that contribute to the acquired immunological barrier. Regardless of the lineage, IELs possess cytotoxic and immunoregulatory properties that are key to regulating homeostatic crosstalk between the innate and acquired immunological barriers and commensal microbiota, and their dysfunction has been implicated in gastrointestinal disease \[[@B104-toxins-12-00146]\].

### 3.2.2. Lamina Propria {#sec3dot2dot2-toxins-12-00146}

The subepithelial lamina propria is the site were effector immune cells of the intestinal immune system can be found \[[@B105-toxins-12-00146]\], these include numerous innate immune cells such as macrophages (M~∅~) and innate lymphoid cells (ILCs) and the acquired immune lymphoid B and T cells \[[@B105-toxins-12-00146]\]. The intestine is known to represent the largest pool of tissue M~∅~ in the body \[[@B106-toxins-12-00146],[@B107-toxins-12-00146]\]. These M~∅~ are innate immune effectors with potent phagocytic and bactericidal activities \[[@B11-toxins-12-00146],[@B96-toxins-12-00146],[@B108-toxins-12-00146]\], but unlike other macrophage populations, they inflict minimal inflammatory collateral tissue damage \[[@B13-toxins-12-00146],[@B96-toxins-12-00146]\]. This distinct property could be ascribed to high expression of phagocytosis-promoting genes such as Mertk, Cd206, Gas6, Axl, Cd36, Itgav, and Itgb5 \[[@B109-toxins-12-00146],[@B110-toxins-12-00146]\], as well as low or lack of expression of receptors associated with innate immune activation, such as receptors for LPS (CD14), Fcα (CD89), Fcγ (CD64, CD32, and CD16), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) \[[@B108-toxins-12-00146]\]. This special functional adaption of resident intestinal M~∅~ allows them to maintain local tissue homeostasis in part by preventing excessive immune reactions to commensal microbiota and food antigens that might otherwise elicit chronic inflammation and tissue damage \[[@B111-toxins-12-00146]\]. Resident intestinal M~∅~ also efficiently remove apoptotic cells and foreign debris and contribute to the repair and remodeling of damaged tissues \[[@B112-toxins-12-00146],[@B113-toxins-12-00146]\]. Collectively, these unique properties ascribe intestinal M~∅~ to the maintenance of intestinal homeostasis \[[@B112-toxins-12-00146],[@B113-toxins-12-00146]\].

In addition to M~∅~, a large population of ILCs is also located within lamina propria \[[@B114-toxins-12-00146]\]. This mixed population of ILCs can be classified based on their cytokines and transcription factors, including natural killer cells, ILC1, ILC2, or ILC3 \[[@B115-toxins-12-00146],[@B116-toxins-12-00146],[@B117-toxins-12-00146],[@B118-toxins-12-00146]\]; respectively, these ILCs are phenotypically and functionally similar to the T helper (T~H~) cell subpopulations T~H~1, T~H~2, and T~H~17 \[[@B114-toxins-12-00146]\]. These ILCs have cytotoxic and immunoregulatory properties that allow them to rapidly respond to and orchestrate the host response against gastrointestinal threats and also maintain epithelial integrity and tissue homeostasis \[[@B119-toxins-12-00146]\].

A number of acquired lymphoid cell populations are also found within the subepithelial lamina propria. Both conventional CD4^+^ and CD8^+^ T cells are found and they perform immunoregulatory and cytotoxic activities, respectively \[[@B105-toxins-12-00146],[@B120-toxins-12-00146],[@B121-toxins-12-00146]\]. Immunoglobulin (IgA)-producing B1 cells are also present \[[@B105-toxins-12-00146]\]; the IgA antibodies produced by their differentiated plasma cells are selectively transported across the epithelium into the intestinal lumen where it helps to prevent microbial invasion by decreasing their motility and adhesion to the surface of the epithelium \[[@B122-toxins-12-00146],[@B123-toxins-12-00146]\].

### 3.2.3. Gut-Associated Lymphoid Tissue (GALT) and Mesenteric Lymph Nodes (MLNs) {#sec3dot2dot3-toxins-12-00146}

A series of events must occur in order for the above-mentioned acquired lymphoid cells to become activated and drive an acquired immune response. M cells must sample and transfer luminal antigens and intact microorganisms to underlying M~∅~ and dendritic cells, which then migrate the Peyer's patches (PP) of the gut-associated lymphoid tissues (GALT) and/or draining mesenteric lymph nodes (MLN) where they convene with T~H~ cells to carry out antigen presentation. Although the events are less well characterized in the PP than MLN, it is believed they are analogous \[[@B124-toxins-12-00146]\]; in short, antigen-specific T~H~ cells become activated during antigen presentation, and then can assist with the activation of antigen-specific B cells, which clonally expand within germinal centers and differentiate into IgA secreting plasma cells.

3.3. Cross-Talk between IECs and Immune Cells {#sec3dot3-toxins-12-00146}
---------------------------------------------

Bidirectional communication between IECs and immune cells facilitates protection from microbial invasion, tissue homeostasis, and repair. This cross-talk is mediated in part by secreted cytokines \[[@B12-toxins-12-00146],[@B13-toxins-12-00146],[@B14-toxins-12-00146],[@B15-toxins-12-00146]\], many of which are commonly produced by immune cells and IECs \[[@B10-toxins-12-00146],[@B14-toxins-12-00146]\]. Some of these cytokines include TGF-α, IL-1, IL-10, IL-15, IL-8, IL-1α, and β, IL-6, TNF-α, MCP-1, CCL20, and GM-CSF \[[@B14-toxins-12-00146],[@B125-toxins-12-00146]\]. IECs also possess receptors for various cytokines, which allows them to respond to immune cell signals. For example, it has been reported that goblet cell mucus production and properties can be directly affected by IL-10 produced by M~∅~ and T-cells within the lamina propria \[[@B126-toxins-12-00146]\]. The expression of IEC TJ proteins can also be inhibited by TNF-α, IFN-γ, and the interleukins IL-2, IL-4, and IL-8, which results in increased gut paracellular permeability \[[@B127-toxins-12-00146]\]. Also, the binding of IL-1 to its receptor on IECs amplifies the secretion of IEC pro-inflammatory cytokines \[[@B128-toxins-12-00146]\].

4. In-vitro Intestinal Epithelial Barrier Models {#sec4-toxins-12-00146}
================================================

Although primary cells are most biologically and physiologically similar to the gastrointestinal epithelial barrier, their short-life span and rapid loss of differentiated characteristics limit their use for in vitro studies \[[@B129-toxins-12-00146],[@B130-toxins-12-00146]\]. Instead, immortalized cell lines of animal and human origin including Caco-2, IPEC-1, and IPEC-J2 IECs have been extensively utilized as in vitro models of the intestinal epithelium to study the effects of mycotoxins on intestinal barrier function. These cell lines have been used at various differentiation states, proliferative versus differentiated, for example, to simulate different intestinal microenvironments \[[@B131-toxins-12-00146],[@B132-toxins-12-00146]\]. Undifferentiated IECs present as a tumorigenic phenotype and do not display cell polarity \[[@B131-toxins-12-00146],[@B133-toxins-12-00146]\]; they also appear similar to dividing cells in tissue undergoing regeneration or repair after damage \[[@B132-toxins-12-00146],[@B134-toxins-12-00146]\]. In contrast, differentiated cells mimic the mature small intestinal barrier in that they have defined epithelial characteristics such as TJs and microvilli, which are lacking in undifferentiated cells \[[@B135-toxins-12-00146]\].

4.1. Caco-2 {#sec4dot1-toxins-12-00146}
-----------

Human Caco-2 cells have been the most widely used IEC line in recent decades \[[@B136-toxins-12-00146]\]; Caco-2 is a cancer-derived cell line originally isolated from a human colon adenocarcinoma \[[@B137-toxins-12-00146]\]. However, once differentiated after 18--21 days of culture post-confluence, they become a homogenously polarized monolayer of enterocyte-like cells with apical and basolateral membranes, a brush border with microvilli and TJs \[[@B138-toxins-12-00146],[@B139-toxins-12-00146],[@B140-toxins-12-00146],[@B141-toxins-12-00146]\]. Caco-2 cells have also been shown to express TLRs and produce various cytokines \[[@B140-toxins-12-00146],[@B142-toxins-12-00146]\].

4.2. IPEC-1 and IPEC-J2 {#sec4dot2-toxins-12-00146}
-----------------------

IPEC-1 and IPEC-J2 are two other IEC lines that have been used as in vitro models of the intestinal barrier. Both IPEC lines were derived from the porcine small intestine. IPECs are spontaneously immortalized non-transformed and non-carcinoma cell lines, established from normal IECs \[[@B143-toxins-12-00146],[@B144-toxins-12-00146]\]. IPEC-1 was derived from the jejunum and ileum of piglets less than 12 hours old. The IPEC-J2 cell line was originally isolated from the jejunum of neonatal unsuckled pigs \[[@B139-toxins-12-00146],[@B143-toxins-12-00146],[@B145-toxins-12-00146]\]. Both IPECs are able to spontaneously differentiate into multiple IEC types \[[@B139-toxins-12-00146]\], and a continuous polarized monolayer and TJ structure can be formed after differentiation \[[@B144-toxins-12-00146]\]. Compared to Caco-2, the IPEC-1 and IPEC-J2 IECs attain a homogenous appearance and express various differentiation markers within a shorter period of time; within 10 days and 1--2 weeks of culturing post-confluence, respectively \[[@B143-toxins-12-00146],[@B146-toxins-12-00146]\], and the IPEC-J2 line is more morphologically and functionally differentiated than the IPEC-1 line \[[@B144-toxins-12-00146]\]. Since the pig intestine closely resembles the human intestine genetically and physiologically, IPECs have been used to model the human intestinal barrier \[[@B129-toxins-12-00146],[@B144-toxins-12-00146]\].

4.3. In-vitro Cell Culture Systems {#sec4dot3-toxins-12-00146}
----------------------------------

In vitro models of the intestinal epithelial barrier have traditionally consisted of one-dimensional (1D) monolayers grown on the surface of culture vessels. With this 1D culture system, functional IEC characteristics, such as cell polarity, are not well defined \[[@B147-toxins-12-00146]\], and misleading results can possibly be obtained. Alternatively, a two-dimensional (2D) monoculture system can be achieved by growing IECs on microporous permeable membrane supports \[[@B148-toxins-12-00146],[@B149-toxins-12-00146]\]; this system structurally mimics the apical and basolateral sides of the intestine and leads to the development of polarized IECs. Most reviewed cytotoxicity studies ([Table 1](#toxins-12-00146-t001){ref-type="table"}) have been conducted using a 1D monoculture system and the 2D monoculture system has been extensively applied to study the effects of mycotoxins on intestinal barrier function parameters such as transepithelial electrical resistance (TEER) and TJ protein expression.

More complex 1D and 2D co-culture systems that are more physically and functionally similar to the intestinal barrier have also been established. These co-culture systems involve cultivating more than one cell type together within one culture system \[[@B129-toxins-12-00146],[@B150-toxins-12-00146],[@B151-toxins-12-00146]\]. The IEC + immune cell co-culture system involving permeable membrane supports is one such established 2D co-culture model \[[@B140-toxins-12-00146]\].

5. Effects of Selected Mycotoxins on Intestinal Barrier Function {#sec5-toxins-12-00146}
================================================================

5.1. Cytotoxic Effects of Individual or Combined Mycotoxins on IECs {#sec5dot1-toxins-12-00146}
-------------------------------------------------------------------

### 5.1.1. Individual Mycotoxins {#sec5dot1dot1-toxins-12-00146}

The cytotoxicity of selected mycotoxins has been evaluated using various IEC models on the basis of cell viability ([Table 1](#toxins-12-00146-t001){ref-type="table"}) as well as proliferation at different concentrations and exposure durations. Mycotoxin cytotoxicity is usually the first parameter to be measured, not only to evaluate the cytotoxicity, but also to identify appropriate mycotoxin concentrations that can be used in follow-up experiments of intestinal barrier function.

The cytotoxicity of DON on different IEC models has been the most studied among the five reviewed mycotoxins. Results using various IEC models including Caco-2, IPEC-1, and IPEC-J2 have shown that DON induces cell death at various concentrations and under different durations of exposure ([Table 1](#toxins-12-00146-t001){ref-type="table"}). A wide range of DON exposure concentrations have been used, ranging from as low as 0.0001 up to 100 μM \[[@B156-toxins-12-00146]\].

A variety of cytotoxicity assays have been applied to assess the cell viability ([Table 1](#toxins-12-00146-t001){ref-type="table"}) and tetrazolium salt MTT (3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyltetrazolium bromide) was most widely used in the reviewed studies, which was shown to be a quick and suitable assay to detect a wide range of mycotoxins for different cell types \[[@B171-toxins-12-00146]\]. In order to avoid false results, more than one cytotoxicity assay has been applied in parallel in some studies, and both similar and discrepant results have been reported \[[@B143-toxins-12-00146],[@B154-toxins-12-00146],[@B164-toxins-12-00146]\]. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS), and Neutral Red (NR) assays have been reported to yield similar cell viability results based on Caco-2 cell viability after 24 h DON exposure \[[@B154-toxins-12-00146]\]. The authors in \[[@B164-toxins-12-00146]\] observed similar cell viability results from the 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2HTetrazolium-5-Carboxanilide (XTT) and NR assays in IPEC-1 cells. However, \[[@B143-toxins-12-00146]\] reported that the lactate dehydrogenase (LDH) leakage assay was less sensitive to DON toxicity compared to the NR assay using both IPEC cell lines. Interestingly, the route of application, apical versus the basolateral side of IECs, appears to influence DON-mediate changes in cell viability, as IPEC-J2 cell viability was more significantly affected when DON is applied to the basolateral side \[[@B157-toxins-12-00146]\]. This differential susceptibility of apical and basolateral surfaces of IECs to DON exposure could be attributed to their biological and functional distinctions such as different protein and lipid compositions \[[@B172-toxins-12-00146]\]. It could also result from the addition of the mucus produced by IPEC- J2 cells covering the apical side of epithelial monolayer \[[@B139-toxins-12-00146]\] as an extra defense line against DON exposure.

The differentiation status of cells may also influence sensitivity to DON exposure. It has been reported that dividing IPEC-J2 and Caco-2 cells, for example, are both more susceptible to DON than their differentiated counterparts \[[@B132-toxins-12-00146],[@B154-toxins-12-00146],[@B159-toxins-12-00146]\]. Differentiation status is typically defined by cell culture duration in some of the reviewed cytotoxicity studies. For example, Caco-2 cells and IPEC-J2 grown on microplates without membrane inserts less than 4 days after seeding were considered undifferentiated, whereas, cells cultured at least 17 days post-seeding were considered differentiated \[[@B153-toxins-12-00146],[@B154-toxins-12-00146]\].

Cell death has been reported to be induced by DON via both apoptosis and necrosis. Caspase 3, a marker for induction of apoptosis, was activated only at a high concentration of DON (6.7 μM) in both IPEC-1 and IPEC-J2 cell lines indicating DON-induced apoptosis \[[@B143-toxins-12-00146]\]. However, necrosis-induced cell death was observed in both differentiated and undifferentiated IPEC-J2 cells after 72 h exposure to DON (0--67 μM) and it was found that the proportion of necrotic cells was concentration-dependent \[[@B158-toxins-12-00146],[@B159-toxins-12-00146]\].

ZEA has also been reported to have adverse effects on IPEC-1, IPEC-J2, and Caco-2 cell viability at various concentrations after different exposure durations ([Table 1](#toxins-12-00146-t001){ref-type="table"}). ZEA is less toxic than DON based on viability studies performed by \[[@B156-toxins-12-00146],[@B161-toxins-12-00146]\]. ZEA appears to induce apoptosis via mitochondrial damage by reducing antioxidant enzyme activities; this may lead to an accumulation of ROS and decreased mitochondrial membrane potential \[[@B46-toxins-12-00146]\]. Necrosis-induced cell death in undifferentiated and differentiated IPEC-J2 cells was also observed after 72 h of exposure to ZEA at 19.9--99.5 μM \[[@B158-toxins-12-00146]\].

AFB1 induced a concentration-dependent decrease in the viability of both undifferentiated and differentiated Caco-2 cells between 24 h and 72 h of exposure \[[@B165-toxins-12-00146]\]. In contrast to DON, the differentiated Caco-2 cells were found to be more susceptible to AFB1 than undifferentiated cells after 72 h of exposure, which could be due to more metabolic and transport enzymes being expressed by the differentiated mature enterocytes \[[@B165-toxins-12-00146]\]. A similar concentration-dependent decrease in Caco-2 cell viability was also observed by \[[@B166-toxins-12-00146]\] after 24 h exposure to a range of AFB1 concentrations (0--100 μM) with LC50s reported to be 5.39 and 6.02 μM obtained from MTT and LDH assays, respectively. AFB1 LC50s obtained from NR assay have also been reported by \[[@B167-toxins-12-00146]\] after Caco-2 cells were exposed to AFB1 (0--100 μM) for 24, 48, and 72 h, which were 10, 2, and 0.5 μM, respectively.

Limited results have been reported on the effects of CIT, MPA, and OTA on cell viability compared to DON and ZEA. CIT has been reported to reduce human HCT116 colon cancer cell viability after 36 h exposure at concentrations of 150 and 300 μM, with the identified LC50 being 300 μM \[[@B169-toxins-12-00146]\]. Authors in \[[@B168-toxins-12-00146]\] reported that CIT exposure also resulted in a decrease in Caco-2 cell viability at 399.6 and 999 μM after 48 h exposure. Cell apoptosis was induced by CIT via endoplasmic reticulum stress \[[@B169-toxins-12-00146]\]. Concerning MPA, \[[@B75-toxins-12-00146]\] reported a concentration-dependent cytotoxic effect of MPA after 48 h exposure in both undifferentiated and differentiated Caco-2 cells, however, LC50 was not obtained with the tested concentration range. However, based on the LC20 calculated in the study, undifferentiated Caco-2 cells appeared to be more susceptible to MPA than differentiated cells \[[@B75-toxins-12-00146]\]. Lastly, the cytotoxic effect of OTA was concentration-dependent, and two LC50s have been reported for the Caco-2 cell line after 24 h of OTA exposure using MTT and LDH assays; these were 21.25 and 16.85 μM, respectively \[[@B166-toxins-12-00146]\]. However, a significantly different OTA LC50 of 145.36 μM was recently reported after 24 h of exposure using Caco-2 cells \[[@B170-toxins-12-00146]\].

Mycotoxins have also been reported to affect cell cycle progression and proliferation. The proliferation of IPEC-1 and IPEC- 2 cells have been reported to be stimulated at lower DON concentrations or inhibited at higher concentrations \[[@B143-toxins-12-00146]\]. For example, 0.67 μM of DON stimulated IPEC-1 cell proliferation after 48 h exposure and stimulated the proliferation of both IPEC-1 and IPEC-J2 cells after 72 h of exposure \[[@B143-toxins-12-00146]\]. However, it is inconclusive whether the stimulated proliferation of IPEC cells resulted from a primary effect of DON or a secondary effect from DON-induced cell death \[[@B157-toxins-12-00146]\] as almost all types of epithelial cells forming monolayers are capable of undergoing self-repair after injury by inducing cell proliferation and migration to the injured site \[[@B173-toxins-12-00146]\].

DON started to inhibit the proliferation of IPEC-1 cells at higher concentrations ranging from 3.4 to 6.7 μM after 48 and 72 h of exposure \[[@B143-toxins-12-00146]\]. The same pattern of effect was also observed for IPEC-J2 cells after 72 h of exposure \[[@B143-toxins-12-00146]\]. The route of application of DON, the apical versus the basolateral side of IECs for example, has also been reported to influence IPEC-J2 cell proliferation. The authors in \[[@B157-toxins-12-00146]\] reported IPEC-J2 proliferation was more significantly stimulated when DON is applied to the basolateral side. Selected mycotoxins other than DON, only OTA has been investigated and it inhibited the proliferation of Caco-2--14 and HT-29-D4 cells by 50% (IC50) at 30 and 20 μM, respectively \[[@B174-toxins-12-00146]\].

At a higher concentration of 6.7 μM, DON decreased the percentage of IPEC-J2 cells in the G0/G1 phase after 24 \[[@B160-toxins-12-00146]\], 48, and 72 h of exposure \[[@B143-toxins-12-00146],[@B157-toxins-12-00146]\]. The authors in \[[@B160-toxins-12-00146]\] also observed a decrease in the percentage of IPEC-J2 cells in the G0/G1 phase at a lower DON concentration of 0.67 μM after 6, 12, and 24 h of exposure. A prolonged IPEC-J2 cell G2/M phase was also induced by DON after 12 and 24 h \[[@B160-toxins-12-00146]\] and 48 h of exposure at 6.7 μM \[[@B143-toxins-12-00146]\]. However, a decrease in cell percentage in the G2/M phase was observed by \[[@B160-toxins-12-00146]\] after 12 h exposure of DON at a lower concentration of 0.67 μM. A prolonged S phase in IPEC-J2 cells was also reported after 6, 12, and 24 h exposure to DON at 0.67 μM, but S phase was reduced at 6.7 μM after 12 h exposure \[[@B160-toxins-12-00146]\].

DON also induced a reduction in the percentage of cells in the G0/G1 phase and G2/M arrest in IPEC-1 cells after 48 and 72 h of exposure at 6.7 μM \[[@B143-toxins-12-00146]\]. A prolonged S phase was also observed in IPEC-1 cells by \[[@B143-toxins-12-00146]\] after 48 h exposure of DON at 6.7 μM. The results on cell proliferation and cell cycle distribution should be considered integrated with the interpretation of the effect of DON on cell growth. The cell cycle shift from G0/G1 to S and G2/M phases and increase in cell proliferation \[[@B173-toxins-12-00146]\] induced by DON at lower concentration might indicate intestinal epithelial cells were undergoing self-repair after DON-induced injury; whereas exposure to higher concentration of DON could have negative impact on intestinal epithelial cell growth by inducing G2/M arrest \[[@B175-toxins-12-00146]\] that allows the cell to repair the DNA damage or misaligned chromosomes at the mitotic spindle \[[@B176-toxins-12-00146]\].

### 5.1.2. Mycotoxin Combinations {#sec5dot1dot2-toxins-12-00146}

Mycotoxin mixtures have also been explored for their effects on IEC cytotoxicity. Concerning DON + ZEA, one of the most prevalent mycotoxin combinations, \[[@B161-toxins-12-00146]\] observed antagonism of DON + ZEA mixtures on IPEC-J2 cell viability after 48 h exposure at both tested exposure combinations (2 μM DON + 40 μM ZEA and 0.5 μM DON + 10 μM ZEA). The authors in \[[@B177-toxins-12-00146]\] also observed an antagonistic effect of DON + ZEA (100 μM/ 40 μM) on HTC116 human cell viability after 24 h exposure, whereas \[[@B155-toxins-12-00146]\], reported that all three combinations of DON + ZEA (10/10, 10/20, and 20/10 μM) resulted in a significant reduction in Caco-2 cell viability compared to individual mycotoxins. With the combination of 10 μM DON + 10 μM ZEA, \[[@B164-toxins-12-00146]\] also observed that the mixtures of ZEA and DON elicited synergistic effects on Caco-2 cell lipid peroxidation and antagonistic effects on DNA synthesis. Lastly, the viability of THP-1 immune cells in a Caco-2 + THP-1 co-culture model was decreased after 48 h exposure to DON + ZEA mixture (LC30/LC30, which was not specified in the article) \[[@B151-toxins-12-00146]\].

5.2. Mycotoxins and Intestinal Permeability {#sec5dot2-toxins-12-00146}
-------------------------------------------

Intestinal permeability is one of the key features reflecting the ability of the intestine to function as the barrier \[[@B178-toxins-12-00146]\]. TEER is commonly used to assess IEC permeability in vitro, and a reduction in TEER has been used as an indicator of mycotoxin-induced epithelial damage \[[@B152-toxins-12-00146]\]. Non-cytotoxic concentrations of tested mycotoxins were usually chosen for TEER studies in the reviewed studies to eliminate the effect of uncontrolled cell death on a reduction in TEER \[[@B179-toxins-12-00146]\].

Paracellular tracer flux assays are often applied following the measurement of TEER to investigate if the potential cause of the observed decrease in TEER is increased intestinal epithelial paracellular permeability. The most commonly applied in vitro paracellular markers include fluorescence compounds (e.g., lucifer yellow, LY), or fluorescent-labeled compounds such as fluorescein isothiocyanate (FITC)-dextran and FITC-insulin \[[@B180-toxins-12-00146]\]. As TJs are the major functional components to regulate the paracellular pathway \[[@B181-toxins-12-00146]\], the assessment of TJs at both gene and protein levels can also be performed to further investigate the mechanism by which compromised intestinal barrier function is induced by mycotoxins.

### 5.2.1. Measurement of Transepithelial Electrical Resistance (TEER) {#sec5dot2dot1-toxins-12-00146}

The impact of DON on TEER has been extensively studied using various in vitro intestinal models. DON decreases TEER values in both concentration- and time-dependent manners regardless of in vitro models used \[[@B152-toxins-12-00146],[@B157-toxins-12-00146],[@B182-toxins-12-00146]\]. The lowest DON concentration that reduced Caco-2 cell TEER values was 0.17 μM after 24 h exposure \[[@B183-toxins-12-00146]\]. A decrease in Caco-2 TEER measurements has also been observed in a Caco-2+ THP-1 co-culture model after 48 h exposure to DON at LC10 and LC30 \[[@B151-toxins-12-00146]\]. In addition to concentration and exposure duration, DON-mediated changes in TEER also depend on cell type. It has been reported that DON reduced IPEC-1 cell TEER measurements more significantly than Caco-2 cells, indicating that IPEC-1 cells are more susceptible to DON exposure \[[@B184-toxins-12-00146]\]. The route of DON application can also affect TEER readings, as it has been reported that the decrease in Caco-2 and IPEC-J2 cell TEER measurements was more pronounced when DON was applied to the basolateral side compared to the apical exposure of DON \[[@B143-toxins-12-00146],[@B152-toxins-12-00146]\]. The authors in \[[@B151-toxins-12-00146]\] reported a decrease in Caco-2 cell TEER readings in a Caco-2 + THP-1 co-culture model after 48 h exposure to both ZEA at LC10 and LC30 (LC10 and LC30 not specified in the article). In a monoculture system, \[[@B164-toxins-12-00146]\] observed that ZEA reduced TEER readings at a concentration of 50 μM over 10 days of exposure duration.

The impact of other mycotoxins on IEC TEER measurements has been less well studied than DON. A decrease in TEER was induced by OTA in Caco-2 and HT-29-D2 cell models \[[@B166-toxins-12-00146],[@B174-toxins-12-00146],[@B185-toxins-12-00146],[@B186-toxins-12-00146]\]. The route of application of OTA can affect TEER readings, as it has been reported that the decrease in HT-29-D2 TEER measurements was more significant and rapid when OTA was applied to the basolateral side compared to the apical exposure of OTA \[[@B174-toxins-12-00146]\]. However, \[[@B185-toxins-12-00146]\] observed the equal toxic effect of OTA on Caco-2 cell TEER measurement on both apical and basolateral exposure. The authors in \[[@B186-toxins-12-00146]\] reported that TEER decrease in Cacao-2/TC7, a clonal derivative of parental Caco-2 cells induced by 48 h exposure to OTA at a concentration up to 200 μM was reversible and the TEER value was fully recovered within 24 h after mycotoxin exposure cessation. AFB1 at 100 μM also decreased the TEER values in Caco-2 cells after 7 days of exposure \[[@B166-toxins-12-00146]\]. Lastly, MPA has also been reported to induce decreased TEER in the Caco-2 cell model after 21 days of continuous exposure at the highest concentration of 190 μM \[[@B75-toxins-12-00146]\].

There are limited data on the effects of mycotoxin mixtures on IEC TEER measurements. Caco-2 cell TEER measurements in the co-culture model were reported to decrease after 48 h exposure to DON + ZEA mixture of two different ratios (LC10/LC10 and LC30/LC30), respectively (LC10 and LC30 were not specified in the article) \[[@B151-toxins-12-00146]\].

Although TEER values that have been reported in the literature have been corrected for the surface area of the membrane inserts used and is typically reported in units of Ω \*cm^2^ \[[@B187-toxins-12-00146]\], other factors that may have impact on TEER measurements should also be considered for purpose of interlaboratory comparisons, including temperature, cell passage number, the composition of cell culture medium, and duration of cell culture \[[@B188-toxins-12-00146]\].

### 5.2.2. Assessment of the Expression of TJ Proteins {#sec5dot2dot2-toxins-12-00146}

DON exposure has been reported to induce alterations in the expression of TJs at both gene and protein levels in various in vitro IEC models and contradictory effects have been reported ([Table 2](#toxins-12-00146-t002){ref-type="table"}). Up-regulation of gene expression has been often observed, whereas a decrease in protein expression has been reported ([Table 2](#toxins-12-00146-t002){ref-type="table"}). The reduction in protein levels associated with the rise in mRNA levels could indicate a compensatory mechanism in place for repair \[[@B183-toxins-12-00146],[@B189-toxins-12-00146]\]. The inconsistent findings emphasize that analyses of mRNA and protein expression should be performed in parallel since the mRNA level does not necessarily predict the amount of protein \[[@B190-toxins-12-00146],[@B191-toxins-12-00146]\].

In contrast to DON exposure, \[[@B166-toxins-12-00146]\] observed a decrease in mRNA expression of CLDN3 and OCLN in Caco-2 cells after AFB1 exposure (0--30 μM), but no changes in CLDN4 mRNA expression was observed. OTA exposure decreased in Caco-2 cell mRNA expression of CLDN3, CLDN4, and OCLN \[[@B166-toxins-12-00146]\]. This inhibitory effect at the transcription level could be explained by its ability to form DNA adducts \[[@B67-toxins-12-00146],[@B71-toxins-12-00146],[@B72-toxins-12-00146]\]. A decrease in protein expression of CLDN3 and CLDN4 has also been reported \[[@B185-toxins-12-00146],[@B192-toxins-12-00146]\].

### 5.2.3. Measurement of Flux of Paracellular Markers {#sec5dot2dot3-toxins-12-00146}

DON induced a dose-dependent increase in the apical to basolateral transport of fluorescence compounds LY and 4 kDa FITC-dextran in Caco-2, IPEC-1 and IPEC-J2 cell lines \[[@B152-toxins-12-00146],[@B189-toxins-12-00146],[@B193-toxins-12-00146]\]. The results on the paracellular passage of 4 kDa FITC--dextran also indicated that IPEC-1 exhibited more sensitivity to DON than Caco-2 cells \[[@B184-toxins-12-00146]\].

It has also been reported that OTA did not affect IEC permeability to 20 and 40 kDa FITC-dextran \[[@B194-toxins-12-00146]\], indicating that the intestinal epithelial cells still partially retain their barrier function during OTA exposure, and that larger molecules are selectively excluded, which is also in agreement with DON exposure.

5.3. Effects of Mycotoxins on Translocation of Intestinal Microorganisms {#sec5dot3-toxins-12-00146}
------------------------------------------------------------------------

In addition to increased intestinal permeability and dysfunctional mucosal immune system, impaired intestinal barrier function is also associated with translocation of luminal antigens \[[@B92-toxins-12-00146],[@B178-toxins-12-00146],[@B195-toxins-12-00146],[@B196-toxins-12-00146]\], which is another endpoint that has been used to investigate the effects of mycotoxins on the intestinal barrier. In vitro studies have shown that DON promoted transepithelial passage and invasion of *Salmonella typhimurium* in both differentiated and undifferentiated IPEC-J2 cells; the increased transepithelial passage of *S. typhimurium* was concentration-dependent \[[@B132-toxins-12-00146]\]. DON also increased the transepithelial passage of *Escherichia coli* in IPEC-1 and IPEC-J2 cells \[[@B184-toxins-12-00146],[@B189-toxins-12-00146]\]. MPA did not promote non-invasive *E. coli* to cross the intestinal epithelium in an in vitro study with Caco-2 cells \[[@B75-toxins-12-00146]\].

6. Effect of Selected Mycotoxins on the Intestinal Immune System {#sec6-toxins-12-00146}
================================================================

Selected mycotoxins also have cytotoxic effects on immune cells. A 0.85 μM DON induced apoptosis in the RAW264.7 macrophage cell line \[[@B197-toxins-12-00146]\]. The apoptosis of Jurkat human T cell line was induced by DON in the concentration range tested (0.85--3.4 μM) \[[@B198-toxins-12-00146]\]. Concerning *Penicillium* mycotoxins, CIT, OTA, and MPA induced cell death and inhibited proliferation of bovine macrophage cell line (BoMacs) in a concentration-dependent manner \[[@B199-toxins-12-00146]\]. A decrease in cell viability of THP-1 cells, human leukemia monocytic cell line, was observed in a Caco-2+THP-1 co-culture system after 48 h exposure to ZEA LC30 (LC30 not specified in the article) \[[@B151-toxins-12-00146]\].

Host mucosal immune response to the invasion of luminal antigens/pathogens requires coordination between IECs and immune cells. Being part of the intestinal innate immune system, IECs serve as dynamic sensors for luminal microbes by expressing PRRs such as TLRs. IECs can also direct the mucosal immune response by producing important chemokines and cytokines that are responsible for the recruitment of immune cells and the induction of the inflammatory response \[[@B10-toxins-12-00146],[@B93-toxins-12-00146]\].

Measuring the expression of cytokine and PRR at gene or protein level has been an endpoint that is commonly used to evaluate the effects of selected mycotoxins on the intestinal immune system using in vitro IEC models. At 2 μM of DON exposure, DON has been reported to up-regulate the expression of IPEC-J2 cell IL1-α, IL1-β, IL-6, IL-8, TNF-α, and MCP1 genes after 48 h of exposure, whereas, 0.5 μM exposure simulated expression of IL1-β, IL-6, and IL-8 genes, and down-regulated expression of IL1-α and MCP1 genes \[[@B200-toxins-12-00146]\]. The up-regulatory effect of DON on IL-6, TNF-α, and IL1-β through the NF-κB pathway was also observed in IPEC-J2 cells after 24 h of DON exposure within the concentration range of 0.34 μM to 6.7 μM \[[@B162-toxins-12-00146]\]. DON also reportedly induced a concentration-dependent increase in the secretion of IL-8 protein by Caco-2 cells through NF-κB after 48 h exposure \[[@B201-toxins-12-00146]\], and \[[@B194-toxins-12-00146]\] reported an increase in IL-8 protein secretion by Caco-2 cells after 12 h, which was associated with NF-κB, PKR, and p38 pathways.

The effect of ZEA on the modulation of cytokine gene expression was carried out using the IPEC-1 and IPEC-J2 cell lines. At a higher concentration of 40 μM, ZEA up-regulated IL1-α, IL1-β, IL-6, IL-8, TNF-α, and MCP1 after 48 h exposure by IPEC-J2 cells, whereas ZEA at 10 μM only stimulated the gene expression of IL1-α, IL1-β, and IL-8 \[[@B200-toxins-12-00146]\]. A stimulatory effect on IFN-λ and IL-4 gene expression was observed in IPEC-1 after 1 h of exposure to 25 μM of ZEA \[[@B23-toxins-12-00146]\]. However, contradictory results have also been reported in other studies. The authors in \[[@B163-toxins-12-00146]\] observed no significant effects on the expression of assessed cytokine genes after IPEC-1 cells were exposed to 10 μM of ZEA for 24 h, including TNF-α, IL1-β, IL-6, IL-8, IL-12p40, IFN-λ, MCP1, IL-10, IL-18, and CCL20, and 10 μM and 25 μM of ZEA exhibited no effect on the expression of IPEC-1 cell IL-8 and IL-10 genes after 24 h of exposure \[[@B164-toxins-12-00146]\].

As for the effect of other mycotoxins, in Caco-2 cells, the protein expression of IL-8 was stimulated in a concentration-dependent manner by MPA at concentrations ranging from 78 μM to 780 μM after 48 h of exposure \[[@B75-toxins-12-00146]\]. Whereas, \[[@B194-toxins-12-00146]\] reported OTA did not have a significant impact on protein secretion of IL-8 in Caco-2 cells. Lastly, \[[@B23-toxins-12-00146],[@B163-toxins-12-00146]\] observed an increase in the expression of TLR2, TLR3, TLR4, and TLR8 genes in IPEC-1 cells after 10 h exposure to 10 μM of ZEA and 1 h exposure to 25 μM of ZEA, respectively.

Exposure of porcine pulmonary alveolar macrophages (PAM) to 0.025 ug/ml DON enhanced the phagocytosis of *S. typhimurium* by macrophages by modulating the macrophage cytoskeleton \[[@B202-toxins-12-00146]\]. The phagocytosis of *Mycobacterium avium ssp. Paratuberculosis* (MAP) by BoMacs was also enhanced by OTA \[[@B203-toxins-12-00146]\]; the other *Penicillium* mycotoxins (CIT and MPA) that this group investigated did not show this stimulatory effect on macrophage phagocytosis \[[@B203-toxins-12-00146]\].

7. In-Vitro Assessment of Efficacy of Risk Mitigation {#sec7-toxins-12-00146}
=====================================================

7.1. Strategies to Counteract Mycotoxin Contamination {#sec7dot1-toxins-12-00146}
-----------------------------------------------------

In an attempt to mitigate the risk of mycotoxin contamination in food and feed, different pre-and post-harvest physical (e.g., crop rotation, thermal treatment, and irradiation), chemical (e.g., acids/bases and absorbents), and biological (e.g., microbial and enzymatic degradation) strategies have been deployed \[[@B27-toxins-12-00146],[@B204-toxins-12-00146],[@B205-toxins-12-00146],[@B206-toxins-12-00146],[@B207-toxins-12-00146]\]. Besides these conventional mitigation methods, nanotechnology may be an innovative solution to mycotoxin contamination \[[@B208-toxins-12-00146]\]. It is not possible in this review to discuss all the approaches; instead, the discussion will focus on remediation strategies that are most widely used in the animal feed industry, especially the use of mycotoxin adsorbents as feed additives.

Among all approaches, the addition of mycotoxin adsorbents to animal feeds, also referred to as "mycotoxin binders", one of the two classes of mycotoxin detoxifying agents \[[@B204-toxins-12-00146]\], is one of the most widely applied and promising remediation approaches to reduce risk of mycotoxicosis in farm animals \[[@B209-toxins-12-00146],[@B210-toxins-12-00146],[@B211-toxins-12-00146],[@B212-toxins-12-00146]\]. Mycotoxin adsorbents bind mycotoxins in the gastrointestinal tract after the contaminated feed is ingested \[[@B207-toxins-12-00146]\], and the bioavailability of the mycotoxins is reduced by the formation of toxin-adsorbent complexes, which are later excreted in the feces \[[@B204-toxins-12-00146]\]. Mycotoxin absorbents can be classified as either silica-based inorganic compounds, or carbon-based organic polymers \[[@B213-toxins-12-00146]\]. The inorganic absorbents are further sub-grouped into aluminosilicate minerals (clays, including bentonites, montmorillonites, hydrated sodium calcium aluminosilicate, and zeolites), activated charcoal (AC), and synthetic polymers (e.g., cholestyramine). The aluminosilicate minerals are the most widely studied of the silica-based inorganic mycotoxin absorbents \[[@B211-toxins-12-00146],[@B213-toxins-12-00146]\]. The efficacy of inorganic absorbents depends on the physio-chemical structure of both adsorbent and mycotoxin \[[@B206-toxins-12-00146],[@B211-toxins-12-00146],[@B214-toxins-12-00146]\]; this includes the total charge and charge distribution of adsorbents and mycotoxins, adsorbent pore size, and accessible surface area, as well as mycotoxin polarity, solubility, and three-dimensional structure \[[@B204-toxins-12-00146],[@B206-toxins-12-00146],[@B211-toxins-12-00146],[@B212-toxins-12-00146]\]. The efficacy of aluminosilicate adsorbents for reducing aflatoxin B~1~ (AFB~1~) bioavailability is fairly efficient \[[@B206-toxins-12-00146]\], but their binding capacity to other mycotoxins is limited \[[@B206-toxins-12-00146],[@B214-toxins-12-00146],[@B215-toxins-12-00146]\]. In contrast, AC has been reported to effectively bind to DON, ZEA, AFB1, fumonisin B1, and OTA, but it can reduce the absorption of some micronutrients which jeopardize the nutritional value of the feed \[[@B204-toxins-12-00146],[@B211-toxins-12-00146],[@B214-toxins-12-00146],[@B216-toxins-12-00146]\]. Cholestyramine is the most well-known of the synthetic polymers and has been shown to be an effective adsorbent for FB~1~, OTA, and ZEA \[[@B210-toxins-12-00146],[@B212-toxins-12-00146],[@B214-toxins-12-00146],[@B217-toxins-12-00146]\]. Its high cost limits its practical use as a mycotoxin adsorbent \[[@B218-toxins-12-00146]\], and inorganic binders are typically added to feeds at high concentrations to account for their low efficiency \[[@B216-toxins-12-00146]\]. Lastly, since the degradation of bound mycotoxins after they have been excreted is relatively slow, this is another ecological disadvantage of using inorganic adsorbents \[[@B207-toxins-12-00146]\].

A commonly used organic adsorbent is yeast cell wall (YCW) from *Saccharomyces cerevisiae* yeast strains \[[@B204-toxins-12-00146]\]. The major functional fractions of YCW responsible for mycotoxin binding include β-D-glucan and α-D-mannan (glucomannan), which bind to mycotoxins via hydrogen bonding and van-der-Waal forces \[[@B219-toxins-12-00146],[@B220-toxins-12-00146],[@B221-toxins-12-00146],[@B222-toxins-12-00146],[@B223-toxins-12-00146],[@B224-toxins-12-00146]\]. The YCW has been shown effective at binding a wide-spectrum of mycotoxins including DON, T-2 toxins, AFB~1~, ZEA, and OTA \[[@B207-toxins-12-00146],[@B219-toxins-12-00146],[@B222-toxins-12-00146],[@B223-toxins-12-00146],[@B224-toxins-12-00146],[@B225-toxins-12-00146],[@B226-toxins-12-00146],[@B227-toxins-12-00146],[@B228-toxins-12-00146],[@B229-toxins-12-00146],[@B230-toxins-12-00146],[@B231-toxins-12-00146],[@B232-toxins-12-00146],[@B233-toxins-12-00146]\]. Heat or acid treatment can further increase the mycotoxin-binding capacity of YCW \[[@B229-toxins-12-00146]\]. Another advantage of YCW products is that they are biodegradable, and therefore the toxin-binder complexes do not accumulate in the environment after being excreted in the feces \[[@B219-toxins-12-00146]\]. The use of lactic acid bacteria (LAB) as an organic dietary mycotoxin-adsorbing agent has recently gained interest \[[@B204-toxins-12-00146]\]. LAB are a group of Gram-positive and non-sporulating bacteria \[[@B233-toxins-12-00146]\], and the strain of LAB that is used to bind to mycotoxins is *Lactobacillus rhamnosus* \[[@B204-toxins-12-00146],[@B213-toxins-12-00146]\]. With glucomannan as the functional component affecting mycotoxin binding capability, the mechanism of LAB is thought to be similar to that of YCW \[[@B204-toxins-12-00146]\].

The second class of mycotoxin detoxifying agents is referred to as mycotoxin modifiers. These agents, which include microorganisms and their enzymes, can be applied to reduce the risk of mycotoxicity by biotransforming mycotoxins to less toxic metabolites \[[@B204-toxins-12-00146]\]. Many commercially available mycotoxin detoxifying agents contain a combination of these two classes, capable of both degradation and adsorption. The authors in \[[@B234-toxins-12-00146]\] conducted a study assessing the efficacy of 20 commercial products incubated under aerobic and anaerobic conditions to detoxify DON and ZEA. Their study revealed that only one out of 20 products under anaerobic incubation was effective at completely degrading DON after 24 h and only one tested product completely degraded ZEA under both incubation conditions after 24 h. All the other products incubated under both aerobic and anaerobic conditions showed maximum DON detoxification of only 17%, and only the other four products showed a reduction of ZEN ≥60% \[[@B234-toxins-12-00146]\].

7.2. In-Vitro Assessment of Mycotoxin Absorbents {#sec7dot2-toxins-12-00146}
------------------------------------------------

The efficacy of mycotoxin adsorbents has been assessed using both in vitro chemical and cell-based bioassays \[[@B231-toxins-12-00146],[@B235-toxins-12-00146],[@B236-toxins-12-00146]\]. With in-vitro chemical assay, the method involves simulating pH conditions in the gastrointestinal tract of different species during adsorbent-mycotoxin co-incubation, and this is followed by chemical chromatographic analysis such as high-performance liquid chromatography with fluorometric detection \[[@B205-toxins-12-00146],[@B230-toxins-12-00146],[@B231-toxins-12-00146],[@B232-toxins-12-00146],[@B234-toxins-12-00146]\], ultraviolet light detection \[[@B237-toxins-12-00146]\], liquid chromatography-tandem mass spectrometry \[[@B238-toxins-12-00146]\], or gas chromatography \[[@B235-toxins-12-00146]\]. Several adsorption isotherm models have been used following the chromatographic analyses to quantify the adsorption performance of tested adsorbents including the Hill, Langmuir, Freundlich, Brunauer--Emmett--Teller (BET), and non-ideal competitive adsorption (NICA) models \[[@B228-toxins-12-00146],[@B230-toxins-12-00146],[@B232-toxins-12-00146]\]. In a study assessing the binding capacity of various yeast-based products to ZEA, AFB~1,~ and OTA, the most suitable models were the Hill model for ZEA, the Langmuir model for AFB~1,~ and the Freundlich model for OTA \[[@B232-toxins-12-00146]\]. When assessing the binding capacity of YCW products and hydrated sodium calcium aluminosilicate to ZEA, \[[@B228-toxins-12-00146]\] reported that the Hill model was or more suitable than the Freundlich model for evaluating YCW adsorption efficacy, but less suitable for HSCAS (hydrated sodium calcium aluminosilicate) adsorbents.

In vitro cell-based bioassays have been less utilized for the assessment of mycotoxin adsorbent efficacy. The endpoints of assessment have included cell viability, proliferation, and TEER measurement \[[@B231-toxins-12-00146],[@B235-toxins-12-00146],[@B236-toxins-12-00146]\]. Different cell lines derived from various species and tissues have been used in assessment studies including Caco-2, NIH/3T3-LNCX murine fibroblasts, and MCF-7 human breast cells \[[@B231-toxins-12-00146],[@B235-toxins-12-00146]\]. A study using the differentiated Caco-2 cell line demonstrated that adsorbents such as AC, aluminosilicate minerals, cholestyramine, mannans, and β-glucans exhibited no significant cytotoxicity; however, cholestyramine induced a decrease in cell viability \[[@B235-toxins-12-00146]\]. In the same study, all tested adsorbents except for cholestyramine mitigated the cytotoxic effects of DON, maintaining higher cell viability than even the control \[[@B235-toxins-12-00146]\]. A study using NIH/3T3-LNCX murine fibroblasts also indicated AC showed the highest binding affinity to DON based on cell viability assessment \[[@B231-toxins-12-00146]\]. The study using the MCF-7 cell line has shown that AC and aluminosilicate minerals adsorbents were effective in binding ZEA \[[@B231-toxins-12-00146]\]. Lastly, \[[@B236-toxins-12-00146]\] assessed the binding capacity of a YCW product to *Penicillium* mycotoxins (i.e., CIT, OTA, MPA, patulin and penicillic acid) using a bovine macrophage (BoMacs) cell line, with cell proliferation as a bioassay endpoint. Their results showed that YCW was the most effective in protecting BoMacs cells against OTA, followed by CIT among all five mycotoxins. A study has also shown that illite mineral clay was for protecting AFB1- and OTA-mediated reductions in Caco-2 cell TEER measurements \[[@B166-toxins-12-00146]\].

8. Suitability and Limitations of Reviewed Intestinal in Vitro Models {#sec8-toxins-12-00146}
=====================================================================

In vitro cell culture models have been extensively used in toxicology, mostly for assessing organ-specific effects of xenobiotics. However, they hardly represent the complexity of the human and animal body \[[@B239-toxins-12-00146],[@B240-toxins-12-00146]\]. The simplicity of in vitro models compared to in vivo however makes it possible to study toxic MOAs in a reproducible manner that may be difficult to be achieved in vivo \[[@B140-toxins-12-00146]\]. In vitro experiments also allow for dose--response analysis of individual mycotoxin exposure as well as their mixtures \[[@B8-toxins-12-00146]\]. The Caco-2, IPEC-1, and IPEC-J2 cell lines reported in the reviewed studies were able to exhibit adequate differentiated intestinal epithelial characteristics, such as proper formation of TJs and polarization in certain culture conditions, immune response-related molecular markers, as well as responsiveness of these characters to mycotoxin exposure with or without risk mitigation methods such as mycotoxin adsorbents; they could represent physiological models of the intestinal epithelial barrier. While these IEC models are used at their undifferentiation status where polarization is not displayed and proper TJs are not formed, they could also be a representation of pathological models of the intestinal epithelial barrier, such as inflammatory bowel diseases (IBD) \[[@B241-toxins-12-00146]\]; they also appear similar to dividing cells in tissue undergoing regeneration or repair after damage \[[@B132-toxins-12-00146],[@B134-toxins-12-00146]\]. Moreover, in terms of assessing the efficacy of mycotoxin adsorbents, with the presence of cells, the in-vitro cell culture could also detect unpredictable tenside-like activities of adsorbents that could affect cell membrane permeability and result in an increase in cellular uptake and toxicity of mycotoxins \[[@B242-toxins-12-00146]\].

Although in vitro models are useful tools and provide valuable information, results should be interpreted with care as there are some limitations with these in vitro models. First, cell lines lack cellular diversity in the single-cell type system. For example, the Caco-2 cell line is not able to differentiate into goblet cells that are present in vivo, thus, mucins and mucus, which are present under normal physiological conditions, are lacking in vitro \[[@B140-toxins-12-00146],[@B243-toxins-12-00146]\]. Second, in vitro cell models may lack certain phenotypes and characteristics that are exhibited in vivo \[[@B140-toxins-12-00146],[@B243-toxins-12-00146],[@B244-toxins-12-00146],[@B245-toxins-12-00146],[@B246-toxins-12-00146],[@B247-toxins-12-00146],[@B248-toxins-12-00146]\]. For example, the HT-29 human colon cancer cell line cannot form proper TJs under certain growth conditions, whereas the T84 human colon cancer cell line is an excellent model to examine epithelial barrier function due to its high TEER properties \[[@B139-toxins-12-00146]\]. Also, the TEER of Caco-2 cells was reported to be smaller than in vivo \[[@B249-toxins-12-00146]\], and neither Caco-2, T84 nor IPEC-J2 cells express claudin-2 \[[@B250-toxins-12-00146]\]. Third, cell culture conditions, such as passage number, media formulation, and culture time, can also affect the conditions of cell lines \[[@B139-toxins-12-00146],[@B251-toxins-12-00146]\]. Other limitations include a lack of relevant factors occurring in vivo, immortalization, limited survival, and metabolic imbalance \[[@B231-toxins-12-00146],[@B252-toxins-12-00146]\].

To date, limited studies have investigated the effects of mycotoxins on the intestinal barrier functions using 2D co-culture models. However, an IEC + immune cell co-culture system may be more appropriate than monocultures to study the effects of mycotoxins on the intestinal barrier function because 2D co-culture models better represent the epithelial structure and function in vivo. This 2D system enables the study of cell--cell interactions by both direct cell contact and soluble factors that are secreted between IECs and immune cells, depending on the co-culture set-up \[[@B129-toxins-12-00146],[@B253-toxins-12-00146]\]. However, 2D co-culture models do have some limitations. Compared to 3D co-culture models, 2D co-culture models have reduced cell--cell interactions, lack cell--matrix interactions, and may be lacking in complete tissue architecture \[[@B254-toxins-12-00146]\]. When compared to monoculture models, a limitation of 2D co-culture is that a wider range of variables could affect the outcomes of co-culture models including cell culture conditions, the size and ratio of different cultured cell populations, and time scale of the experiments with the interactions between populations considered \[[@B255-toxins-12-00146]\].

9. Conclusion and Discussion {#sec9-toxins-12-00146}
============================

Mycotoxins present an issue worldwide due to their ability to contaminate agricultural commodities and to pose a health risk to both humans and animals that have ingested the contaminated food and feed. Climate change will likely favor more mycotoxin contamination \[[@B2-toxins-12-00146],[@B7-toxins-12-00146]\]. Since mycotoxins are commonly present as co-contaminants, it is not only important to understand their MOAs, many of which are unknown, but also to understand how they interact with each other to affect exposed humans and animals.

Since the intestine is the major site of mycotoxin interaction following oral exposure, understanding these interactions at the intestinal level is critical for risk assessment and mitigation. The intestine functions as a semi-permeable physical and immunological barrier and is the major site of nutrient absorption. Therefore, any adverse effects mycotoxins pose to the intestine, such as changes in intestinal permeability, cytokine production, and cell viability may be a constraint to animal health and production.

In vitro cell culture models of the intestinal barrier have been used to mimic oral exposure to mycotoxins. These intestinal models are usually based on a monolayer epithelial cell culture system, sometimes grown on membrane inserts to better mimic the intestinal barrier for assessing the intestinal transport of mycotoxins, the impact of different routes of exposure, and how mycotoxin exposure impacts the translocation of pathogens \[[@B143-toxins-12-00146],[@B148-toxins-12-00146],[@B152-toxins-12-00146],[@B256-toxins-12-00146]\].

A number of different mitigation approaches, including the use of mycotoxin adsorbents, have been developed and applied to help reduce the adverse effects of mycotoxins on animals, but their efficacy varies depending on physio-chemical properties of both adsorbents and mycotoxins. Given this, there is an ongoing need for the development of novel more effective mycotoxin adsorbents and for their efficacy assessment. Given that in-vitro cell culture can help to better understand what actually happens at the intestinal level \[[@B235-toxins-12-00146]\], the possible cytotoxic effects of mycotoxin adsorbents on the gut epithelium and their mycotoxin binding efficacy can be assessed using in-vitro cell-based bioassays based on functional parameters such as cell viability and TEER values \[[@B231-toxins-12-00146],[@B235-toxins-12-00146]\].

Most of the cell culture studies collated in this review are based on the in vitro monoculture system. However, it may be more appropriate and efficient to co-culture various cell types, such as the IEC + macrophage co-culture model, to simulate a more complex in-vitro system that better reflects the intestinal mucosa physiologically and morphologically. Although there are limitations associated with cell culture models, in vitro monoculture, or even better a co-culture system, is an efficient approach for initial toxicity assessment of mycotoxins and their mixtures and assessment of adsorbent efficacy. It is also an efficient approach for determining the MOAs for both individual and combined mycotoxins that exhibit species- and organ-specific toxicity at the cellular and molecular level.

10. Suggestions for Future Research {#sec10-toxins-12-00146}
===================================

Although in vitro and in vivo toxicity data for DON is abundant, toxicity data for other mycotoxins is limited, especially with regards to *Penicillium* mycotoxins, which are commonly detected in forage, particularly silage \[[@B257-toxins-12-00146],[@B258-toxins-12-00146]\]. There is also a lack of in vitro and in vivo toxicity data concerning the combined toxic effects of mycotoxins. Moreover, exposure guidelines throughout the world are all based on individual mycotoxins, and multi-exposure has raised a question about the health risk of co-occurring mycotoxins. As in most cases, feed and food can be contaminated with multiple mycotoxins and the combined toxicity of mycotoxin mixtures cannot always be predicted based on their individual toxicity \[[@B5-toxins-12-00146]\]. Thus, more studies should investigate the effects of multi-mycotoxin exposure to provide guidance for toxicological evaluation and reflect on the suitability of current mycotoxin exposure guidelines.

In vitro and in vivo mycotoxin toxicity studies have focused more on monogastric animals over ruminants, as ruminants are considered more resistant to mycotoxins due to the ability of rumen microbes to detoxify mycotoxins into non-toxic compounds \[[@B259-toxins-12-00146]\]. However, the safety of ruminant species should be more thoroughly considered. Certain mycotoxins with antimicrobial properties, for example, can impair the function of the rumen and intestinal microflora, thus, decreasing their capacity to degrade mycotoxin \[[@B25-toxins-12-00146],[@B27-toxins-12-00146]\]. Moreover, ruminant animals in certain production stages are more susceptible to mycotoxins. For example, ruminants in the transition period have a negative energy balance and are particularly sensitive to mycotoxin contamination in feed \[[@B25-toxins-12-00146]\]. Also, newly-weaned ruminants can be prone to mycotoxin exposure because the rumen microbiota is not fully established or functional to protect young ruminants from mycotoxins \[[@B260-toxins-12-00146]\]. Some mycotoxins may by-pass the rumen intact instead of being detoxified in the rumen \[[@B79-toxins-12-00146]\].

In vitro cell culture systems (monoculture or co-culture systems) could be a useful and effective approach to start with for studying organ- and species-specific complicated issues of mycotoxin toxicity at the cellular and molecular levels such as interactions between different mycotoxins \[[@B151-toxins-12-00146]\], comparative toxicity of mycotoxins, and their metabolites \[[@B155-toxins-12-00146]\]. Moreover, cell culture systems could be appropriate methods to study biotransformation of mycotoxins in animal cells, for example, the cell models could express certain enzymes such as Cytochromes P450 (CYPs) that might interact with tested mycotoxins by biotransforming them to the resulting metabolites \[[@B16-toxins-12-00146],[@B261-toxins-12-00146]\].
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###### 

Summary of effects of individual mycotoxins on intestinal epithelial cell (IEC) viability.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mycotoxin   IEC model                       Exposure Duration                         Tested Exposure Concentration                            Cytotoxicity Assay                     LC50/Effective Concentration (ECs)   References
  ----------- ------------------------------- ----------------------------------------- -------------------------------------------------------- -------------------------------------- ------------------------------------ -----------------------------
  **DON**     Caco-2 (differentiated)         24 h                                      0, 1.39, 4.17, 12.5, 37.5 μM                             LDH release                            EC: 37.5 μM                          \[[@B152-toxins-12-00146]\]

              Caco-2                          48 h                                      0, 0.05, 0.1, 0.3, 0.5, 1, 3, 5, 10 μM                   Luminescent Cell Viability Assay       LC50 =1.3 uM; EC: 0.5--10μM          \[[@B153-toxins-12-00146]\]

              Caco-2                          24 h                                      0, 0.25, 1, 2.5, 5, 10 μM                                MTS Assay                              LC50 = 10 μM                         \[[@B154-toxins-12-00146]\]

              Neutral Red                     LC50 = 3.7 μM                                                                                                                                                                  

              72 h                            0, 0.25, 1, 2.5, 5, 10 μM                 MTS Assay                                                LC50 = 4.3 μM                                                               

              Neutral Red                     LC50 = 3.7 μM                                                                                                                                                                  

              Caco-2 (differentiated)         24 h                                      0, 0.25, 1, 2.5, 5, 10 μM                                MTS Assay                              LC50 \> 10 μM                        \[[@B154-toxins-12-00146]\]

              Neutral Red                     LC50 \> 10 μM                                                                                                                                                                  

              72 h                            0, 0.25, 1, 2.5, 5, 10 μM                 MTS Assay                                                LC50 \> 10 μM                                                               

              Neutral Red                     LC50 \> 10 μM                                                                                                                                                                  

              Caco-2                          72 h                                      1--150 μM                                                Neutral Red                            LC50 = 21.5 μM; EC: 10 μM            \[[@B155-toxins-12-00146]\]

              MTT Assay                       LC50 = 25 μM; EC: 10 μM                                                                                                                                                        

              Caco-2                          24 h                                      0, 0.001, 0.01, 0.1, 1, 10, 25, 50, 100 μM               CCK-8                                  LC50 = 21.94 μM                      \[[@B156-toxins-12-00146]\]

              48 h                            LC50 = 9.39 μM                                                                                                                                                                 

              72 h                            LC50 = 6.18 μM                                                                                                                                                                 

              IPEC-1                          24 h                                      0, 0.34, 0.67, 1.7, 3.4, 6.7 10.2, 13.4 μM               MTT Assay                              EC: 1.7, 3.4, 10.2, 13.4 μM          \[[@B143-toxins-12-00146]\]

              48 h                            EC: 0.34 μM; 1.7--13.4 μM                                                                                                                                                      

              72 h                            EC: 0.34 μM; 1.7- 13.4 μM                                                                                                                                                      

              IPEC-1 (in serum-free media)    24 h                                      0, 0.67, 6.7 μM                                          LDH release                            NA                                   

              48 h                            EC: 6.7 μM                                                                                                                                                                     

              72 h                            EC: 6.7 μM                                                                                                                                                                     

              IPEC-1 (in complete media)      24 h                                      0, 0.67, 6.7 μM                                          Neutral Red                            EC: 0.67, 6.7 μM                     

              48 h                            EC: 6.7 μM                                                                                                                                                                     

              72 h                            EC: 6.7 μM                                                                                                                                                                     

              IPEC-1 (in serum-free media)    24 h                                      0, 0.67, 6.7 μM                                          Neutral Red                            EC: 0.67, 6.7 μM                     

              48 h                            EC: 6.7 μM                                                                                                                                                                     

              72 h                            EC: 6.7 μM                                                                                                                                                                     

              IPEC-J2                         24 h                                      0, 0.34, 0.67, 1.7, 3.4, 6.7 10.2, 13.4 μM               MTT Assay                              EC: 0.34, 3.4, 6.7, 13.4 μM          \[[@B143-toxins-12-00146]\]

              48 h                            EC: 1.7--13.4 μM                                                                                                                                                               

              72 h                            EC: 1.7--13.4 μM                                                                                                                                                               

              14 d                            0, 0.17, 0.34, 0.67, 1.02, 1.34, 1.7 μM   0.67, 1.02, 1.34, 1.7 μM                                                                                                             

              IPEC-J2                         24 h                                      0, 0.67, 6.7 μM                                          LDH release                            NA                                   \[[@B143-toxins-12-00146]\]

              48 h                            EC: 6.7 μM                                                                                                                                                                     

              72 h                            NA                                                                                                                                                                             

              IPEC-J2                         24 h                                      0, 0.67, 6.7 μM                                          Neutral Red                            EC: 0.67, 6.7 μM                     \[[@B143-toxins-12-00146]\]

              48 h                            EC: 6.7 μM                                                                                                                                                                     

              72 h                            EC: 6.7 μM                                                                                                                                                                     

              IPEC-J2 (in serum-free media)   24 h                                      0, 0.67, 6.7 μM                                          Neutral Red                            EC: 0.67, 6.7 μM                     \[[@B143-toxins-12-00146]\]

              48 h                            EC: 6.7 μM                                                                                                                                                                     

              72 h                            EC: 6.7 μM                                                                                                                                                                     

              IPEC-J2 (basolateral)           24 h                                      0, 0.67, 1.7, 6.7, 13.4 μM                               DAPI staining                          NA                                   \[[@B157-toxins-12-00146]\]

              48 h                            EC: 6.7, 13.4 μM                                                                                                                                                               

              72 h                            EC: 6.7, 13.4 μM                                                                                                                                                               

              IPEC-J2                         24 h                                      0, 0.034, 0.085, 0.17, 0.34, 0.85, 1.7, 3.4, 17, 34 μM   Neutral Red                            EC: 0.85--34 μM                      \[[@B132-toxins-12-00146]\]

              IPEC-J2                         72 h                                      0, 3.4, 8.5, 17, 25.5, 34 μM                             Annexin-V-FITC/ PI                     EC: 8.5--34 μM                       \[[@B158-toxins-12-00146]\]

              IPEC-J2                         72 h                                      0, 3.4, 17, 34, 51, 67 μM                                Annexin-V-FITC/ PI                     LC50 = 10.47 μM                      \[[@B159-toxins-12-00146]\]

              IPEC-J2 (differentiated)        72 h                                      0, 3.4, 17, 34, 51, 67 μM                                Annexin-V-FITC/ PI                     LC50 = 46.9 μM                       \[[@B159-toxins-12-00146]\]

              IPEC-J2                         6 h                                       0, 0.67, 6.7 μM                                          CCK-8 Assay                            EC: 0.67, 6.7 μM                     \[[@B160-toxins-12-00146]\]

              12 h                                                                                                                                                                                                           

              24 h                                                                                                                                                                                                           

              48 h                                                                                                                                                                                                           

              72 h                                                                                                                                                                                                           

              IPEC-J2                         48 h                                      0, 0.25, 0.5, 1, 2 μM                                    MTT Assay                              LC50 = 1.83μM; EC:1--2 μM            \[[@B161-toxins-12-00146]\]

              IPEC-J2                         24 h                                      0, 0.43, 0.85, 1.7, 3.4, 6.7 μM                          CCK-8 Assay                            EC: 0.85--6.7 μM                     \[[@B162-toxins-12-00146]\]

  **ZEA**     Caco-2                          72 h                                      1--150 μM                                                Neutral Red                            LC50 = 15 μM                         \[[@B155-toxins-12-00146]\]

              MTT Assay                       LC50 = 25 μM                                                                                                                                                                   

              Caco-2                          24 h                                      0, 0.001, 0.01, 0.1, 1, 10, 25, 50, 100 μM               CCK-8                                  LC50 = 62.67 μM                      \[[@B156-toxins-12-00146]\]

              48 h                            LC50 = 56.96 μM                                                                                                                                                                

              72 h                            LC50 = 34.36 μM                                                                                                                                                                

              IPEC-1                          24 h                                      0, 0.1, 1, 10, 100 μM                                    XTT Assay                              EC: 100 μM                           \[[@B163-toxins-12-00146]\]

              IPEC-1                          24 h                                      0, 0.1, 1, 10, 100 μM                                    XTT Assay                              EC: 100 μM                           \[[@B164-toxins-12-00146]\]

              0, 0.1, 1, 10, 100 μM           Neutral Red                               EC: 100 μM                                                                                                                           

              IPEC-J2                         48 h                                      0, 5, 10, 20, 40 μM                                      MTT Assay                              EC: 10, 40 μM                        \[[@B161-toxins-12-00146]\]

              IPEC-J2                         48 h                                      0, 15.5, 31, 62, 124, 248 μM                             MTT Assay                              LC50 = 62.1 μM;\                     \[[@B46-toxins-12-00146]\]
                                                                                                                                                                                        EC: 62--248 μM                       

              IPEC-J2                         72 h                                      0, 19.9, 39.8, 44.73, 59.7, 79.6, 99.5 μM                Annexin-V-FITC/PI                      EC: 44.73--99.5 μM                   \[[@B158-toxins-12-00146]\]

              Caco-2                          24 h                                      0, 0.032, 0.16, 0.32, 1.6, 3.2 μM                        MTT Assay                              EC: 3.2 μM                           \[[@B165-toxins-12-00146]\]

  **AFB1**    48 h                            EC: 0.32---3.2 μM                                                                                                                                                              

              72 h                            EC: 1.6--3.2 μM                                                                                                                                                                

              Caco-2 (differentiated)         24 h                                      0, 0.032, 0.16, 0.32, 1.6, 3.2 μM                        MTT Assay                              EC: 1.6 μM                           \[[@B165-toxins-12-00146]\]

              48 h                            EC: 1.6--3.2 μM                                                                                                                                                                

              72 h                            EC: 0.16--3.2 μM                                                                                                                                                               

              Caco-2                          24 h                                      0, 0.032, 0.16, 0.32, 1.6, 3.2 μM                        LDH release                            EC: 1.6--3.2 μM                      \[[@B165-toxins-12-00146]\]

              48 h                            EC: 0.32--3.2 μM                                                                                                                                                               

              72 h                            EC: 0.32--3.2 μM                                                                                                                                                               

              Caco-2 (differentiated)         24 h                                      0, 0.032, 0.16, 0.32, 1.6, 3.2 μM                        LDH release                            EC: 3.2 μM                           \[[@B165-toxins-12-00146]\]

              48 h                            EC: 0.032--3.2 μM                                                                                                                                                              

              72 h                            EC: 0.032--3.2 μM                                                                                                                                                              

              Caco-2                          24 h                                      0, 1,3, 10, 30, 100 μM                                   MTT Assay                              LC50 = 5.39 μM\                      \[[@B166-toxins-12-00146]\]
                                                                                                                                                                                        EC: 1--100 μM                        

              LDH release                     LC50 = 10 μM\                                                                                                                                                                  
                                              EC: 3--100 μM                                                                                                                                                                  

              Caco-2                          24 h                                      0--100 μM                                                Neutral Red                            LC50 = 10 μM                         \[[@B167-toxins-12-00146]\]

              48 h                            LC50 = 2 μM                                                                                                                                                                    

              72 h                            LC50 = 0.75 μM                                                                                                                                                                 

  **CIT**     Caco-2                          48 h                                      0, 399.6, 999 μM                                         Crystal Violet staining (CVS)          EC: 399.6, 999 μM                    \[[@B168-toxins-12-00146]\]

              HCT116                          36 h                                      0, 75, 150, 300 μM                                       Fluorescein diacetate (FDA) staining   LC50 = 300 μM; EC: 150- 300 μM       \[[@B169-toxins-12-00146]\]

  **MPA**     Caco-2                          48 h                                      0, 0.0078, 0.078, 0.78, 7.8, 78, 780 μM                  MTS Assay                              LC50 \> 780 uM                       \[[@B75-toxins-12-00146]\]

              Caco-2 (differentiated)                                                                                                                                                                                        

  **OTA**     Caco-2                          24 h                                      0, 1, 3, 10, 30, 100 μM                                  MTT Assay                              LC50 = 21.25 μM; EC: 1--100 μM       \[[@B166-toxins-12-00146]\]

              LDH release                     LC50 = 16.85 μM; EC: 1--100 μM                                                                                                                                                 

              Caco-2                          24 h                                      1--200 μM                                                MTT Assay                              LC50 = 145.36 μM                     \[[@B170-toxins-12-00146]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

toxins-12-00146-t002_Table 2

###### 

Summary of effects of selected mycotoxins on tight junction gene and protein expression.

  Mycotoxins   IEC model   Exposure Duration   Exposure Concentration     Effects of Selected Mycotoxins on Gene and Protein Expression of TJs   References                        
  ------------ ----------- ------------------- -------------------------- ---------------------------------------------------------------------- --------------------------------- -----------------------------
  DON          Caco-2      24 h                0, 1.39, 4.17, 12.5 μM     Increase in CLDN1, CLDN3, CLDN4, OCLN, ZO-1                            Decrease in CLDN1, CLDN3, CLDN4   \[[@B152-toxins-12-00146]\]
               Caco-2      24 h                0, 0.17, 1.7, 17 μM        Increase in CLDN4, OCLN                                                Decrease in CLDN4                 \[[@B183-toxins-12-00146]\]
               Caco-2      48 h                0, 5, 10, 20, 50, 100 μM   N/A                                                                    Decrease in CLDN4                 \[[@B184-toxins-12-00146]\]
               IPEC-1      48 h                0, 5, 10, 20, 50 μM        N/A                                                                    Decrease CLDN3, CLDN4             \[[@B184-toxins-12-00146]\]
               IPEC-1      48 h                0.67, 6.7 μM               N/A                                                                    Decrease in ZO-1                  \[[@B143-toxins-12-00146]\]
               IPEC-J2     48 h                0.67, 6.7 μM               N/A                                                                    Decrease in ZO-1                  \[[@B143-toxins-12-00146]\]
               IPEC-J2     12 h                0, 4 μM                    Decrease in CLDN3; increase CLDN4, OCLN, ZO-1                          Decrease CLDN3, CLDN4             \[[@B189-toxins-12-00146]\]
  AFB1         Caco-2      7 days              0, 1,3, 10, 30 μM          Decrease in CLDN3, OCLN                                                N/A                               \[[@B166-toxins-12-00146]\]
  OTA          Caco-2      24 h                0, 100 μM                  N/A                                                                    Decrease in CLDN3 and CLDN4       \[[@B185-toxins-12-00146]\]
               Caco-2      24 h                0, 100 μM                  N/A                                                                    Decrease in CLDN3 and CLDN4       \[[@B192-toxins-12-00146]\]
               Caco-2      7 days              1, 3, 10, 30 μM            Decrease in CLDN3, CLDN4 and OCLN                                      N/A                               \[[@B166-toxins-12-00146]\]
